Epodion Side Effects

For safety with respect to transmissible agents, see Precautions.
Clinial Trial Data: The most frequent adverse drug reaction during treatment with Epoetin alfa is a dose-dependent increase in blood pressure or aggravation of existing hypertension. Monitoring of the blood pressure should be performed, particularly at the start of therapy. Other common adverse drug reactions observed in clinical trials of Epoetin alfa are diarrhoea, nausea, headache, influenza-like illness, pyrexia, rash, vomiting, deep vein thrombosis, pulmonary embolism, seizures. Influenza-like illness including headache, joint pains, myalgia, and dizziness and tiredness, may occur especially at the start of treatment. Frequencies may vary depending on the indication see table as follows.
The overall safety profile of Epoetin alfa was evaluated in 142 subjects with chronic renal failure and in 765 subjects with cancer who participated in placebo-controlled, double-blind clinical registration trials. Adverse drug reactions reported by ≥0.2% of Epoetin alfa-treated subjects in these trials, additional clinical trials and from post­-marketing experience are listed as follows by SOC and frequency. Frequencies are defined as: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very Rare (<1/10,000), Not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness: (See table).


Click on icon to see table/diagram/image